Vortioxetinum 10 mg

The short version: 4.5 mg of lithium is not a tested dose, and no retrieved study supports it for bipolar stabilization.

The 2009 trial tested lithium at therapeutic serum levels, which requires roughly 600 to 1200 mg per day, not 4.5 mg [1]. The 4.5 mg figure is about 1/200th of a standard dose. No study in the retrieval tested that amount. A 2022 pilot trial used standard lithium doses and found no added benefit over divalproex alone, with a 3-fold higher dropout risk in the lithium arm [3]. That trial does not speak to 4.5 mg either.

The evidence for quetiapine plus lithium at standard doses is real. The 2009 trial found continued quetiapine prolonged time to any mood recurrence versus placebo (HR 0.29, 95% CI 0.23 to 0.38), and switching to lithium at therapeutic levels was also superior to placebo (HR 0.46, 95% CI 0.36 to 0.59) [1]. A 4-year naturalistic study of 232 patients found quetiapine plus lithium gave the best maintenance, with 80% surviving without a major depressive episode and the lowest dropout rate at 24% [2].

But 4.5 mg of lithium is homeopathic territory. It contains no pharmacologically active lithium. No retrieved record tested it, so there is no evidence it stabilizes anything. The combination works at standard doses; at 4.5 mg, the lithium is inert.

Confidence: high that 4.5 mg lithium is untested and pharmacologically meaningless. The evidence for the combination at standard doses is moderate, from one RCT and one naturalistic study, both industry-adjacent.